Progression-free survival | Overall survival | ||||||
---|---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | ||
Gender | Females | (ref) | (ref) | 0.03 | |||
Males | 0.65 | 0.43–0.96 | 0.03 | 0.64 | 0.43–0.94 | ||
Age | Per 1 year increase | 0.99 | 0.97–1.02 | 0.63 | 0.98 | 0.96–1.01 | 0.16 |
WHO PS | 0 | 0.84 | 0.57–1.24 | 0.38 | 0.59 | 0.39–0.88 | 0.009 |
1–2 | (ref) | (ref) | |||||
unknowna | |||||||
Location primary tumor | Right | 0.74 | 0.45–1.23 | 0.25 | 1.21 | 0.72–2.02 | 0.48 |
Left | 0.87 | 0.57–1.35 | 0.54 | 1.14 | 0.74–1.76 | 0.55 | |
Rectum | (ref) | (ref) | |||||
Primary tumor resected | Yes | 0.78 | 0.41–1.51 | 0.46 | 0.78 | 0.40–1.50 | 0.49 |
No | (ref) | (ref) | |||||
Number of metastatic sites | 1 | (ref) | (ref) | ||||
2 | 1.05 | 0.66–1.67 | 0.84 | 1.31 | 0.82–2.10 | 0.27 | |
>2 | 1.23 | 0.77–1.96 | 0.40 | 1.51 | 0.95–2.40 | 0.09 | |
Prior chemotherapy | F | (ref) | (ref) | ||||
F + Oxa | 0.99 | 0.52–1.92 | 0.99 | 2.50 | 1.25–5.00 | 0.009 | |
F + Oxa + Bev | 1.91 | 0.52–6.96 | 0.33 | 3.53 | 0.94–13.2 | 0.06 | |
Prior radiotherapy | Yes | 0.71 | 0.29–1.75 | 0.46 | 0.85 | 0.35–2.10 | 0.73 |
No | (ref) | (ref) | |||||
Liver metastases | Yes | 0.88 | 0.57–1.37 | 0.58 | 1.18 | 0.76–1.82 | 0.64 |
No | (ref) | (ref) | |||||
Lung metastases | Yes | 1.09 | 0.73–1.61 | 0.67 | 1.50 | 1.01–2.21 | 0.044 |
No | (ref) | (ref) | |||||
TOP1 CN (CEN-20) | Per 1 unit increase | 0.99 | 0.90–1.10 | 0.88 | 0.98 | 0.89–1.08 | 0.72 |
TOP1 CN (CEN-20) | >median (4.46) | 0.95 | 0.65–1.40 | 0.79 | 0.92 | 0.62–1.35 | 0.66 |
≤ median (4,46) | (ref) | (ref) | |||||
TOP1/CEN-20 ratio | Per 1 unit increase | 0.99 | 0.56–1.74 | 0.97 | 1.02 | 0.61–1.70 | 0.95 |
TOP1/CEN-2 ratio | Per 1 unit increase | 1.10 | 0.85–1.35 | 0.58 | 1.00 | 0.79–1.27 | 0.98 |
TOP1/CEN-20 ratio | <1.5 (ref) | ||||||
≥1.5 | 0.73 | 0.47–1.13 | 0.16 | 0.75 | 0.48–1.17 | 0.21 |